



Inflammation in the **brain damages and destroys brain cells, speeding aging and atrophy of your brain**. Causing dementia, Alzheimer’s, Parkinson's and other degenerative brain diseases

.

Our Solution: JOTROL **(NASDAQ: JUNS)**

JUPITER NEUROSCIENCES, INC

CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS

This Presentation contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. Factors that could cause such differences, but are not limited to, are our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management, expected market growth, our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this Presentation and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.

MARKET, INDUSTRY AND OTHER DATA

This presentation includes market and industry data and forecasts that the Company has developed from independent research reports, publicly available information, various industry publications, other published industry sources or the Company’s internal data and estimates. Independent research reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. Although the Company believes that the publications and reports are reliable, the Company has not independently verified the data and makes no representation or warranty with respect to the accuracy of such information. Any and all trademarks and trade names referred to in this presentation are the property of their respective owners. The Company’s internal data, estimates and forecasts are based on information obtained from trade and business organizations and other contracts in the markets in which it operates and management’s understanding of industry conditions. Although the Company believes that such information is reliable, the Company has not had such information verified by any independent sources.

The Jupiter Neurosciences Story

2015

Founded with the goal of developing a highly bioavailable resveratrol

Virtual Concept

With strong academia and other collaborations, including UM, Harvard, MIT, Georgetown and MCRI

Phase I Trial

Financed by NIA/NIH, results showed ~9X increased bioavailability, published in Journal of AD and AAPS Open

Initial Focus on Rare Diseases

Opened IND for MPS-1, but data triggered broadening of scope

Breakthrough Pre-Clinical Data

In Parkinson's Disease, triggering Phase IIa trial

Management

Strong management team and advisors with extensive international experience and a track record for successfully building organizations that can take a product from inception to commercialization

Christer ”Chris” Rosén

Chairman, CEO & Founder. Serial entrepreneur, inventor and team builder with over 20 years in executive Biotech positions.

Alexander Rosén

Our CAO and Co-Founder. Went from professional golf to finance and administration, spending the last 6 years as Controller and head of admin in the Biotech industry.

Marshall Hayward, Ph.D

Our CSO and Co-Founder is an experienced pharma product developer, with VP and C-suite roles in large and small pharmaceutical companies, with several product approvals achieved in large and small companies.

Alison D. Silva

Our CBO/President and Director brings today’s view on the rare disease business and financing. Former CEO for a publicly traded rare disease company. Founder of the Orphan Group, a consulting firm regarding all aspects of rare diseases.

Saleem Emasri, CPA

Our CFO is the owner of Titan Advisory Services, LLC. Saleem has years of background in taking companies public. He also spent over 10 years as Senior Manager at PWC focusing on the Pharma Industry. .

JUPITER NEUROSCIENCES, INC

Scientific Advisory Board

Scientific Team comprising of world-renowned specialists in their respective fields, providing hands-on involvement and valuable assistance to JUNS

Li-Huei Tsai, Ph.D.

Li-Huei is Professor and Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology and one of the leading Alzheimer's researchers in the world. Actively guiding us in planning of our AD studies.

Raymond Turner, MD, Ph.D.

Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center, Washington, DC. He earlier conducted an Alzheimer's trial with resveratrol generating positive data. Can't wait to be the Principal Investigator for our Phase II trial in Alzheimer's Disease .

Rudolph Tanzi, Ph.D.

Professor at Harvard and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital (MGH). Regarded by many as the authority in the world for developing and predicting success in treatment of Alzheimer's.

Charbel Moussa. MBBS Ph.D.

Associate Professor of Neurology. Director-Laboratory for Dementia and Parkinsonism. Department of Neurology Georgetown University Medical Center.

Shaun Brothers, Ph.D., MBA

Shaun is our lead researcher in pre-clinical development of rare diseases. Associate Professor at U of Miami and one of our Co-Founders.

Claes Wahlestedt, MD, Ph.D.

Our CMO and Co-Founder who primarily works as Professor at U of Miami. Long time leading roles as research head at large pharma companies e.g., AZ and Pfizer.

W. Dalton Ditreich III, Ph.D.

Scientific Director of The Miami Project; Kinetic Concepts Distinguished Chair in Neurosurgery; Sr. Associate Dean for Discovery Science; Co-Director, Institute for Neural Engineering; Professor, Neurological Surgery, Neurology, Biomedical Engineering and Cell Biology

JUPITER NEUROSCIENCES, INC

Resveratrol Mechanism of Action

Pre-clinical animal studies have shown that resveratrol induces mitochondrial biogenesis and reduces inflammation

MITOCHONDRIAL BIOGENESIS

- Promotes mitochondrial biogenesis through indirect AMPK and SIRT1 activation



ANTI-INFLAMMATION

- Effectively scavenges and neutralizes free radicals and other oxidants
- Direct antioxidant ability promotes anti-inflammation



Heidi Cartwright, Prince of Wales Medical Research Institute, Sydney Australia

JUPITER NEUROSCIENCES, INC

Canto, et al. Pharmacological Reviews January 2012, 64 (1) 166-187

Resveratrol MOA and Applications

Resveratrol is a polyphenolic compound that exerts its effects through various mechanisms, including activation of the SIRT1 enzyme, modulation of inflammatory pathways, and regulation of cell signaling cascades.

Antioxidant and DNA Repair

Potent antioxidant properties, scavenging free radicals and preventing oxidative stress, which can contribute to various health benefits. Activates PARP-1, an important protein in DNA repair and stress response.

Anti-Inflammatory

Demonstrated inhibition of pro-inflammatory mediators, such as cytokines and enzymes, thereby reducing inflammation and its associated health risks.

Anti-Cancer

Shown to inhibit pro-inflammatory mediators, such as cytokines and enzymes, thereby reducing inflammation and its associated health risks.

Cardioprotective

Improves cardiovascular health by enhancing endothelial function, reducing blood pressure, and improving lipid profiles.

Neuroprotective Effects

Evidence of neuroprotective properties, including the ability to improve cognitive function, reduce the risk of neurodegenerative diseases, and protect against neuronal damage.

Antibacterial and Antiviral

Significant antibacterial effects against various food-borne pathogens. Inhibits replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2, respectively).

The Resveratrol Story

- Natural polyphenol supplement known for decades as a “miracle product”. ~14,000 scientific papers published.

- Severe GI side effects at therapeutically effective doses has prevented utilization and drug approvals (Turner & MCRI studies)

- **JOTROL, developed by JUNS, the First-in-class oral therapeutic that reaches therapeutic effective levels in the brain and increases energy metabolism, induces mitochondrial biogenesis and reduces inflammation**

Resveratrol (RSV) vs JOTROL

	RSV	JOTROL	
Bioavailability	✗	✓ ✓ ✓	*Phase I study showed ~9 x higher bioavailability than Resveratrol at concentration maximum (Cmax)*
Intellectual Property	✗	✓ ✓ ✓	*Patents granted in USA, Europe, China, Hong Kong and Japan; JOTROL is protected through 2036*
GI Tolerability at Efficacious Dose	✗	✓ ✓ ✓	*Excellent tolerability at therapeutic doses*

JUPITER NEUROSCIENCES, INC

Neuroinflammation and Lack of Mitochondria are Major Causes for Many Diseases

ALZHEIMER'S DISEASE

PARKINSON'S DISEASE

RARE DISEASES

MITOCHONDRIAL DISORDERS

MENTAL DISORDERS

HEALTHSPAN & LONGEVITY
DTC Opportunity

Pipeline Development Strategy: One Phase I study enabling several indications starting directly in Phase II



JUPITER NEUROSCIENCES, INC

Ph I healthy volunteer study to serve as safety/tolerability-enabling trial for launching multiple Ph II programs

MCI/Early-AD

"There is a collective understanding emerging: Alzheimer's will need to be attacked from several directions at once. Drugs like Aduhelm and Leqembi, which focus on the traditional amyloid target, will become only one of many strategies used to tackle the disease" stated by ADDF (Alzheimer's Drug Discovery Foundation)

- Phase II study as a follow-on to the Turner resveratrol (underdosed) AD study that generated several positive results (Turner et. Al)
- NIA grant in application, $16.5 M, for a Phase II study, 12 months study, focusing on blood biomarkers
- "JOTROL, a novel formulation of resveratrol, shows beneficial effects in the 3xTg-AD mouse model", published in Journal of Alzheimer's Disease

JOTROL is Neuroprotective

Motor Dysfunction in MPTP Model of Parkinson's Disease

CONCLUSION: JOTROL™ DEMONSTRATES BENEFICIAL NEUROLOGIC EFFECTS IN PD TRIGGERING A PHASE II A TRIAL







JUPITER NEUROSCIENCES, INC

MELAS

Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes

MELAS is the most common of the 12 acknowledged rare mitochondrial diseases. The commonality might lead to an accelerated approval process for the other diseases within this category. No existing treatment.

Resveratrol stimulates mitochondrial biogenesis and favorably modulates oxidative metabolism

- Beneficial for mitochondrial rare diseases as well as health span & longevity

- Proof of Concept Trial:
  - 10 to 12 patients
  - Evaluate muscle tissue metabolism and Assess blood biomarkers
- Target: Achieve a significant increase in metabolic capacity in muscle tissue
- Positive results can, in addition, have an impact in Longevity and Aging

JUPITER NEUROSCIENCES, INC

Source: * EvaluatePharma 2020

Developments in South-East Asia

- Resveratrol is widely used and accepted in SE Asian markets
- Resveratrol currently approved as a Traditional Chinese Medicine (TCM)
- Business development contracts in place for product expansion
- Target is to get one or more out-licensing deals for China, Malaysia and Singapore during 2025

Direct To Consumer Approach

Following points will be evaluated before we execute, subject to separate financing

- Business plan to be developed focusing on Longevity and Aging
- Many functions can be out-sourced to existing successful DTC entities
- Start-up cost expected to be less than $3 Million
- Present traditional resveratrol sales is ~$200 Million with a projected annual increase of 17%
- Strong interest received from Hong Kong and mainland China
- A 30% market share, premium priced, can generate a $100 M in revenue

Recent events → 2024/2025 Objectives

Significant research and corporate accomplishments despite limited resources; positioned to execute in the second half of 2024 and into 2025

- Phase I completed in healthy volunteers opens fast track to Phase II trials in multiple indications
- Preclinical study in PD (mice) with breakthrough results completed at UM
- NIA new MCI/early AD Phase II study grant subject to approval in Q2 2025
- Phase II studies in PD and possibly MELAS (later) projected to start in early 2025
- Asian strategic development/out-licensing agreement in PD projected in 2025
- DTC product development to be completed in Q3 2025

Contact

Jupiter Neurosciences, Inc.
NASDAQ: JUNS
1001 North US HWY 1, Suite 504
Jupiter, FL 33477
+1 (561) 406-6154
c.rosen@jupiterneurosciences.com
a.silva@jupiterneurosciences.com
www.jupiterneurosciences.com